Plain-English translation of NCT06854653 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called to treat cutaneous T-cell lymphoma—a type of blood cancer that affects the skin—in people whose disease has come back or stopped responding to earlier treatments. The study will first test two different doses of the medication in a smaller group to find the best dose, then test that optimal dose in a larger group of patients.
Current treatment options don't work well enough for everyone with this type of lymphoma, especially once the disease stops responding to earlier therapies. This trial aims to see whether this new treatment can help patients whose options are limited.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly for about 18 months, receiving the medication as an intravenous infusion over one hour on days 1–5 of each cycle. In the first phase, you would have frequent blood draws and skin exams to monitor how well the treatment works and check for side effects. You would also complete quality-of-life questionnaires at each visit. The study continues until your disease improves, you experience unacceptable side effects, or 18 months have passed, whichever comes first.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States